Menu
← Oncology Approval Tracker
FDA DECISION ·
Lonsurf + bevacizumab
trifluridine + tipiracil + bevacizumab · Taiho Oncology
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan regimens and an anti-VEGF biologic. RAS wild-type patients also must have received anti-EGFR therapy.
LAMPGEN ANALYSIS
Why it matters
The action added bevacizumab to a previously approved later-line oral regimen.
What research teams should watch
Verify prior drug classes and synchronize oral dosing, blood counts and infusion visits.
PRIMARY RECORDS